key: cord-1035790-l9rmmllx
authors: Le, Thi Khanh; Paris, Clément; Khan, Khadija Shahed; Robson, Fran; Ng, Wai-Lung; Rocchi, Palma
title: Nucleic acid-based technologies targeting coronaviruses
date: 2020-11-27
journal: Trends Biochem Sci
DOI: 10.1016/j.tibs.2020.11.010
sha: 2a88461dab43e4c74946c7ad244bb99f96f08ae4
doc_id: 1035790
cord_uid: l9rmmllx

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently creating a global health emergency. This crisis is driving a worldwide effort to develop effective vaccines, prophylactics and therapeutics. Nucleic acid (NA)-based treatments hold great potential to combat outbreaks of coronaviruses (CoVs) due to their rapid development, high target specificity, and the capacity to increase druggability. Here, we review key anti-CoV NA-based technologies, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), RNA-targeting CRISPR-Cas systems and mRNA vaccines, and discuss improved delivery methods and combination therapies with other antiviral drugs.

promising solution since they are highly specific (see also druggability), easy to design, and less time consuming to develop compared to conventional therapies. Crucially, by targeting highly-conserved sequences, an NA-based drug could be used to combat multiple viral strains and overcome problems of drug resistance. In this review, we evaluate several key anti-CoV NA-based technologies, including ASOs, siRNAs, RNA-targeting CRISPR-Cas systems, and mRNA vaccines (Figure 1 ), and discuss improved delivery methods and combination therapies with other antiviral drugs.

In principle, any regions in the coronavirus genome can be considered as potential therapeutic targets for antiviral NA-based drugs. However, TNAs should be designed to target highly conserved sequences amongst CoV genomes to prevent potential selective pressures that generate drug-resistant virus mutants. Another benefit of this strategy is to broaden the application of these NA-based drugs to target multiple coronavirus strains using the same compounds. Analysis of SARS-CoV-2 genomes has revealed highly conserved viral regions, including sequences encoding RNA-dependent RNA polymerase (RdRp) and N protein, making them promising targets for developing anti-CoV TNAs [12] . Indeed, a bioinformatics analysis demonstrated that a set of six CRISPR-associated RNAs (crRNAs) designed within these conserved sites are predicted to target 91% of currently sequenced coronaviruses [12] . In addition, targeting host factors using different TNA strategies is worth exploring as this may result in a cellular environment that is unfavourable for viral replication [13, 14] . Moreover, host-targeted TNAs for CoV inhibition can minimize the chance of generating drug-resistant mutants because of the genetic stability of host factors [15] .

Previous studies reported success in blocking viral entry using TNAs to suppress expression of host proteins that are critical for viral infection and progression, such as membrane receptors transmembrane protease serine 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) [16, 17] .

An optimal therapeutic cocktail of multiple NA-based drugs designed to target either a single sequence or multiple sequences could be considered to enhance antiviral effects [18] .

Targeting multiple viral sequences and several different viruses simultaneously has recently been successfully demonstrated for treatment of swine enteric CoVs (SECoVs) [19] . A cocktail of TNAs designed to target both viral and host genes could be used in combination.

Moreover, TNAs can be used in combinational therapies with other antivirals such as nucleoside analogues (e.g. remdesivir, EIDD-2801) [20, 21] , protease inhibitors (e.g.

Journal Pre-proof ritonavir/lopinavir) [22] , and cysteine protease inhibitors (e.g. MDL-28170, ONO 5334) [23] .

This strategy may improve the effectiveness at a lower dose through drug synergy, thereby limiting side effects and reducing the likelihood of drug resistance. Recently, a nucleosidemodified mRNA vaccine expressing different conserved influenza virus antigens has been developed as a universal influenza virus vaccine candidate. This multiple-targeting mRNA vaccine can trigger strong immune responses in a mouse model, protecting against a panel of group 1 influenza A viruses [24] . A similar mRNA vaccination strategy holds promise for CoVs as well.

Most of TNAs to date, including approved therapeutics, are locally administered (eyes, spinal cord), a few of them are systemically delivered or targeted to the liver [9] . As the lungs are a primary site of organ damage during SARS-CoV infection, they have been one of the main targets for therapeutic compounds to impede virus progression [25] . An optimal strategy to increase the efficacy of anti-CoV TNAs is to deliver them directly to the lungs via aerosol [26] . For example, an anti-TGF-β1 siRNA delivered via inhalation significantly inhibited bleomycin-induced pulmonary fibrosis in both acute and chronic mouse models in a dosedependent manner [27] . The current aerosol/inhalation administered ASOs in pre-clinical development and in clinical trials are listed in Table 1 [28] [29] [30] [31] [32] . Together, these results show the great potential of delivering NA drugs via aerosol administration directly to the lungs.

As many antiviral compounds are hydrophobic or only slightly soluble [33] , they require encapsulation within a nanoparticle to enable their delivery. Nanomicelle technology holds great promise for combinational therapy against CoVs, where ASOs and small molecule antivirals would be conjugated together within the same vector for delivery. Lipid-modified ASOs (LASOs) are able to self-assemble into nanomicelles that significantly improved cellular entry without aid of transfection agents [34] [35] [36] . In particular, hydrophobic chemotherapy drugs can be conjugated with these nanomicelles, facilitating their delivery [37] . Holding this advantageous property, a nanomicelle can be encapsulated with anti-CoV small molecules and applied as a combinational therapy that can be administered by aerosol inhalation. ASOs forming nanomicelles can be designed to act on the viral genomes, resulting in synergistic effects of both ASOs and encapsulated drugs in CoV inhibition ( Figure 2 ). Moreover, this strategy could possibly enhance the potency of antiviral nucleoside analogues by combining with ASOs that target the nsp14 protein and thus downregulating ExoN proofreading activity of CoV [20] . In short, the combination of LASO and hydrophobic drugs can represent a new class of therapeutic cocktail to inhibit CoVs including SARS-CoV-2.

J o u r n a l P r e -p r o o f

Regarding the delivery of mRNA vaccines, several strategies already being tested in clinical trials appear promising. CureVac is currently evaluating a mRNA vaccine platform based on protamine-formulated RNA complexes for the delivery of lung and prostate cancer vaccines [38, 39] . Recently, Moderna has put forward a phase 1 clinical trial for a mRNA vaccine against Zika virus delivered by lipid nanoparticle (LNP) (NCT03323398). These mRNA vaccine formulations provide multiple advantages including high potency, ease and costeffectiveness of production and safe administration, and could potentially be applied to the delivery of CoV mRNA vaccines into the body.

ASOs are defined as short, synthetic, single-stranded oligodeoxynucleotides (usually 15-25 nucleotides in length) that can target transcripts through Watson-Crick hybridization [40] .

The resulting DNA:RNA hybrids can lead to cellular RNase H recruitment and cleavage of the RNA in the heteroduplexes by RNase H [41, 42] . Alternatively, ASOs can function in an RNase H-independent manner by disrupting translation of the targeted transcripts via steric hindrance or by modulating pre-mRNA alternative splicing through blocking splicing ciselements and/or affecting RNA structure (known as splice switching oligonucleotides or SSOs) [43, 44] (Figure 2 ). Currently, numerous ASOs are undergoing clinical trials for treatment of a variety of infectious, metabolic, and neurological human diseases, and eight ASO drugs have been approved [40] . Several early studies reported success using ASO technology to target SARS-CoV.

Phosphorodiamidate morpholino-oligomers (PMO), a class of ASOs chemically modified to be uncharged, water soluble, and nuclease resistant, knocked down the target sequences by disruption of either translation or splicing of the pre-mRNA [45, 46] . PMO conjugated with HIV Tat peptide that had previously demonstrated significantly enhanced cellular delivery [47] was explored to target the 5' end of a murine CoV replicase polyprotein containing the AUG translation start site region [48] . These peptide-conjugated PMOs (P-PMO) were shown to effectively enter host cells, block translation of the ORF1ab replicase polyprotein and inhibit CoV growth and proliferation [48] . Further study using P-PMOs specifically targeting conserved RNA elements critical for viral replication or translation such as the transcription regulatory sequences (TRS) located in the 5' untranslated region (UTR) of the SARS-CoV genome demonstrated effective antiviral potency [49] . Another study reported strong antiviral effects of a P-PMO which was designed to base-pair with the 5′ terminus of the CoV RNA genome (called 5TERM PMO) [50] . Accordingly, this ASO reduced viral titers in both cell culture and in vivo mouse models [50] .

J o u r n a l P r e -p r o o f Small interfering RNA (siRNA) against CoVs siRNA technology takes advantage of the cellular RNA interference (RNAi) pathway that uses RNA molecules to interact with complementary mRNAs and subsequently inhibit the expression of a particular gene [51] . Accordingly, synthetic 21-25 nucleotide (nt) double stranded (ds) RNA molecules designed to target the gene of interest are recognized by the host RNA-induced silencing complexes (RISC) which then separate the two strands of RNA.

The RISC-associated antisense strand guides the complex to the specific target sequences, leading to their cleavage and degradation [51] (Figure 3 ). siRNAs have been widely explored to combat various viruses [18] , and several antiviral siRNAs have undergone clinical trials [52, 53] . There have been two FDA-approved siRNAs, along with many clinical trials underway for a multitude of pathologies, and translation times from bench to bedside will hopefully become shorter as the technology matures [54, 55] .

The CoV structural proteins and RdRp have been targeted by siRNAs in a number of studies due to their importance in viral replication and disease progression. Akerström et al.

employed RNAi technology to lower the expression of viral proteins through targeting subgenomic RNAs (sgRNAs) [56] . They developed three siRNAs for targeting accessory proteins 7a/7b, 3a/3b, and the structural protein S. In SARS-CoV infected Vero E6 cells, a significant decrease of virus yield was observed when expressing each siRNA separately, suggesting that the accessory proteins, in addition to the well-characterised S protein, may play an important role during SARS-CoV replication [56] . Moreover, this study reported that the siRNAs can specifically inhibit target sgRNAs without affecting related sequences such as viral genomic RNA or other sgRNAs that contain only two or more mismatches (17/19bp) with the designed siRNA, demonstrating the high sequence-specificity of the technique [56] .

Another strategy aimed to target several structural proteins (S, M, E, and N) synchronously using a set of siRNAs. He et al. reported that a combination of siRNAs at very low concentration inhibiting two structural proteins simultaneously in SARS-CoV infected cells displayed a synergistic effect on reducing viral accumulation, which was not observed with a single siRNA at high concentration [57] . Another study explored the antiviral effect of targeting two genes synchronously by using two different small hairpin RNAs (shRNAs) targeting the M gene of PEDV (porcine epidemic diarrhea virus) and SADS-CoV (swine acute diarrhea syndrome coronavirus) and the N gene of PDCoV, respectively.

Simultaneous expression of these two shRNAs displayed significant downregulation of M and N protein expression and prevented the replication of PEDV, SADS-CoV, and PDCoV simultaneously [19] .

Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated protein 9

(CRISPR-Cas9), the type II CRISPR Cas system from Streptococcus pyogenes, is one of the most frequently used RNA-guided DNA endonuclease systems that determines target sites for dsDNA cleavage via RNA-DNA hybridization between guide RNA (gRNA) and specific DNA target sequences [58] [59] [60] . CRISPR-Cas9 as an antiviral agent can exert its effects through either targeting directly the viral genome or disrupting the expression of host proteins involved in crucial viral activities [61] . The canonical CRISPR-Cas9 system can target dsDNA viruses such as herpesviruses, HPV and HBV, or RNA viruses which have dsDNA intermediates during their life cycle such as HIV [62] .

The native CRISPR-Cas9 form targets DNA exclusively because its binding and catalysis relies on recognition of a protospacer adjacent motif (PAM), a short DNA sequence next to and on the strand opposite the twenty-nucleotide target site in dsDNA [59, 61] . However, studies have engineered CRISPR-Cas9 systems to cleave single stranded RNA (ssRNA) by simultaneously delivering PAM-presenting oligonucleotides (PAMmers) that base pair to specific sites of target ssRNA, mimicking the double stranded target sequence [59, 61] . In addition, the RNA-targeting CRISPR-Cas13d system based on the RNA-guided RNA endonuclease derived from Ruminococcus flavefaciens XPD3002 has opened up potential therapeutic opportunities to combat RNA viruses [63, 64] . The gRNA or CRISPR-associated RNAs (crRNAs) containing a customizable 22-nt spacer sequence leads the associated Cas13d to the RNA target for RNA cleavage and gene silencing [12] . Nguyen et al. have recently presented a strategy to combat SARS-CoV-2 using the CRISPR-Cas13d system with gRNAs consisting of spacer sequences complementary to the target sequences [65] .

They have also designed 10,333 potential gRNAs targeting 10 coding regions of SARS-CoV-2, which specifically recognise the viral RNA genome without disrupting the human transcriptome. As a safe and effective viral vector for gene therapy in clinical experiments, adeno-associated virus (AVV) was considered as a vehicle to deliver the Cas13d effector to the patients [65] . Due to the small size, the Cas13d effector can be packed in the same AVV particle along with up to three different gRNAs, resulting in high efficacy, specificity, and a high barrier to drug resistance ( Figure 4 ).

Recently, a prophylactic antiviral CRISPR-based system (called PAC-MAN) has been explored as a genetic tool to inhibit SARS-CoV-2 and influenza A virus (IAV) [12] . Using a bioinformatics pipeline, the authors identified highly conserved viral sequences across multiple SARS-CoV-2 genomes and designed potential crRNAs for targeting these regions [12] . Further studies on these antiviral CRISPR-Cas systems are warranted and will accelerate the identification of safe and potent CRISPR-based antiviral strategies for treating CoV infections.

NA vaccines, consisting of either DNA or RNA encoding for antigenic proteins, employ the host's transcriptional and translational machinery to produce a disease-specific antigen [66] .

Once DNA vaccine-encoding plasmids are delivered into the host cells, the associated genes are transcribed in the nucleus under the control of eukaryotic promoters and translated in the cytoplasm [67] . In contrast, mRNA vaccines are transcribed from antigencoding template DNA by in vitro transcription (IVT) [67] . Once delivered into the cells, the mRNAs are translated in the cytoplasm to synthesize antigens of interest. The resulting proteins are subsequently processed, presented, and recognized by the immune system, thereby activating a strong humoral and T cell immune response [68] (Figure 5 ).

Numerous studies have demonstrated the safety, tolerance, and high potency of NA vaccines [67, 69, 70] . Moreover, the NA vaccines have a number of advantages over traditional vaccines, including their ability to deliver multiple antigens with one immunization and to stimulate both humoral and cellular immune responses, which makes, for example, tumor escape less probable [67] . mRNA vaccines are potential prophylactic and therapeutic strategies against various infectious diseases [69, 70] and are attractive candidates for responding to the COVID-19 pandemic as they can be rapidly developed and their production can be scaled up within a short period of time [69, 70] . RNA vaccines have several advantages over DNA vaccines, making them a more viable alternative [67, 71] .

HPLC-purified mRNAs containing modified nucleosides could suppress RNA-mediated immune activations and significantly enhanced translation rates compared to unpurified mRNAs [72, 73] . Moreover, self-amplifying RNA (saRNA) vaccines that encode both the antigen of interest and proteins enabling RNA vaccine replication, induce immune responses with considerably lower mRNA inputs [70] . 

The main challenges of TNAs in clinical applications include their safe and efficient in vivo delivery as most NA-molecules exhibit nuclease susceptibility, poor cellular uptake, rapid clearance from circulation, and immunogenicity, as indicated in Table 3 summarizing the pros and cons of each TNA strategy [82] [83] [84] . Extensive chemical modifications are required to enhance NA drug stability and delivery, thereby improving their drug-like properties [9] .

For example, 2ʹ-O-methyl (2ʹ-OMe) modifications of the ribose sugar can significantly enhance nuclease resistance of TNAs and reduce innate immune responses [9, 84, 85] . Of note, up to eight of ten FDA-approved TNAs are administered without any conjugates or delivery vehicles, and only rely on chemical modifications to enhance their delivery efficiency, demonstrating the great potency and importance of chemical modifications [9] . Furthermore, many current TNA researches focus on associating TNAs with conjugations such as mAb, aptamers, or with nanocarriers such as LNP to facilitate their tissue distribution (Table 3) .

The safety of TNAs in clinical applications is a high priority as potential side effects can originate from multiple factors including chemical modifications, treatment duration, dose, or sequence. In particular, host targeted-TNAs may cause unintended toxicities as the downregulation of ACE2, for example, could enhance cellular inflammation and potentially increase mortality in COVID-19 [100] . Undesired immunosuppression events were reported for NA molecules containing specific 2′OMe motifs [84, 85] and severe thrombocytopenia has been observed for two ASOs containing 2'-O-methoxy-ethyl phosphorothioate (2ʹ-MOE PS) modifications, Inotersen and Volanesorsen [83] . Therefore, additional studies on optimizing chemical modifications and delivery methods that could enhance the potency and safety profiles of TNAs are highly warranted. It is worth designing TNAs that target highly conserved sequences among CoVs, so that they can be used against a variety of viral strains and to avoid drug resistance due to selection pressure. Conserved sequences compromise functions that are central to virus life cycles; therefore, mutations occurring in these regions are unlikely to be viable. TNAs can also be designed to target host cellular factors crucial for viral progression. In addition, targeting multiple factors crucial for viral pathogenesis simultaneously by using optimal therapeutic cocktails of TNAs designed to several sequences, or using TNAs along with other antiviral drugs are approaches worth considering. This strategy may enhance antiviral effects, allow for lower drug doses, reduce the likelihood of drug resistance occurring, and stimulate robust immune response. 

Aptamers: structured, short single-stranded oligonucleotides (typically ~20-100 nucleotides) that fold into defined architectures and act as ligands binding to targets such as proteins Druggability: in drug discovery, druggability refers to a biological target that is known to or is predicted to bind with high affinity to a drug-like molecule Several key NA-based strategies against CoV including antisense oligonucleotides (ASOs), small interfering RNAs (siRNA), RNA-targeting CRISPR-Cas systems and mRNA vaccines were discussed in the review. In particular, ASOs, siRNAs and CRISPR-Cas technologies can be used as anti-CoV therapeutics through sequence-specific targeting of RNA viral genome or host cellular genes involved in crucial viral activities (also see Figure 2 ,3,4). Once mRNA vaccines are delivered into the host cells, the mRNAs can be translated into viral proteins that subsequently trigger immune responses (also see figure 5 ).

Association of antisense oligonucleotides (ASOs) with carriers enhances their cellular delivery (1). Alternatively, lipid-modified ASOs (LASO) can self-assemble into nanomicelles (2) , which have the ability to encapsulate hydrophobic drugs such as antiviral small molecules (3) and enter the cells unaided (4) . Once delivered into the cells, ASOs, LASOs, and drugs can be released (5) . ASOs/LASOs base-pair with the target RNA sequences which could be host cellular mRNA or viral RNA genome (6) . The formed DNA:RNA hybrids can induce cleavage of the RNA in the heteroduplexes (through RNase H recruitment and activity), leading to degradation of the targeted sequences (7) . Binding of ASOs/LASOs to the target RNA sequences also can form a steric hindrance blocking translation or modulating alternative splicing, thereby shutting down the gene expression of host genes or disrupting RNA-based viral functions such as translation, replication and transcription (8) . In addition, the conjugated drugs can exert their activities via inhibition of viral processes such as transcription/replication, host entry, and virus assembly & budding (9) . (5), leading to RNA degradation catalyzed by RISC enzyme (6) . As a consequence, these siRNAs can downregulate the expression of target host/viral genes crucial for viral activities, and interrupt viral replication/transcription. Created with BioRender. 

ICTV Virus Taxonomy Profile: Nodaviridae

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Origin and evolution of pathogenic coronaviruses

Coronaviruses: an overview of their replication and pathogenesis

Properties of Coronavirus and SARS-CoV-2

Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology

Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections

Advances in oligonucleotide drug delivery

2020) siRNA could be a potential therapy for COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy

CRISPR-Cas based targeting of host and viral genes as an antiviral strategy

Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2

siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells

A review on current status of antiviral siRNA

Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector

Coronavirus RNA proofreading: molecular basis and therapeutic targeting

Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

New understanding of the damage of SARS-CoV-2 infection outside the respiratory system

Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis

Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis

Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey

Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice

The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis

Multitargeted approach using antisense oligonucleotides for the treatment of asthma

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer

Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain

Hydrophobically modified antisense oligonucleotides comprising a cetal group

Evaluation de l'autonanovectorisation de l'oligonucléotide anti-TCTP comme stratégie innovante pour le traitement des cancers de prostate résistants à la castration

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

) mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

Antisense oligonucleotides: A primer

Antisense Oligonucleotides, A Novel Developing Targeting Therapy

ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy

Pre-mRNA Splicing Modulation by Antisense Oligonucleotides

Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation

Evaluation of antisense mechanisms of action

HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers

Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth

Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers

Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models

Molecular Mechanisms and Biological Functions of siRNA

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

RNA Therapy: Current Status and Future Potential

2020) siRNA therapeutics: a clinical reality

Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S

Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

Programmable RNA recognition and cleavage by CRISPR/Cas9

RNA-guided genetic silencing systems in bacteria and archaea

Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans

The Impact of CRISPR-Cas System on Antiviral Therapy

Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors

Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. , Cell research

The promise of nucleic acid vaccines

RNA-Based Vaccines in Cancer Immunotherapy

2020) mRNA Vaccines: Possible Tools to Combat SARS-CoV-2

Advances in mRNA Vaccines for Infectious Diseases

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

Three decades of messenger RNA vaccine development

Nucleoside Modified mRNA Vaccines for Infectious Diseases

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, proteinencoding mRNA

Vaccines against COVID-19

Evolution of the COVID-19 vaccine development landscape

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

Paving the Road for RNA Therapeutics

Targeting RNA: A Transformative Therapeutic Strategy

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists

The chemical evolution of oligonucleotide therapies of clinical utility

Immunogenicity for antisense oligonucleotides: a risk-based assessment

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

Safety of antisense oligonucleotide and siRNA-based therapeutics

Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

Recent progress in chemically modified siRNAs

RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?

Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Identification of preexisting adaptive immunity to Cas9 proteins in humans

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment

mRNA vaccines -a new era in vaccinology

The emerging role of RNA modifications in the regulation of mRNA stability

SARS-CoV-2 vaccines in development

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms

This review was created by a consortium of volunteer scientists from around the world who 

The authors declare no competing interests.